Images List Premium Download Classic

Dermatitis

Dermatitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods of treating atopic dermatitis with il-31 monoclonal antibodies
Zymogenetics, Inc.
September 14, 2017 - N°20170260267

The present invention relates to methods of treating pruritic diseases, including but not limited to contact dermatitis, atopic dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia wereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination thereof by administering il-31 monoclonal antibodies. The invention further provides the hybridomas ...
Compositions comprising dihydroquercetin for use in methods for treating the effects associated with skin inflammatory ...
Bionoox Suisse Sa
August 31, 2017 - N°20170246141

A method of using a composition including dihydroquercetin, as well as optionally α-tocopherol and/or bisabolol, for treating the effects associated with skin inflammatory disorder, such as those associated with diseases characterized by inappropriate immune response, such as psoriasis, atopic dermatitis and/or urticaria. A process of manufacturing the composition is also described.
Chemical inhibitors of sebocyte function
Bionoox Suisse Sa
August 24, 2017 - N°20170240575

The present discovery pertains to the discovery of certain amphiphilic compounds that may be useful for the management of sebum secretion in subjects with acne, oily skin, or seborrheic dermatitis. These compounds are 1-dialkylphosphorylalkanes with the longest alkyl group being seven or more carbons. Preferably, a compound is dissolved in a dermatologically acceptable vehicle, and delivered to the skin in ...
Dermatitis Patent Pack
Download + patent application PDFs
Dermatitis Patent Applications
Download + Dermatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dermatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Piperazine derivatives as liver x receptor modulators
Vitae Pharmaceuticals, Inc.
August 10, 2017 - N°20170226067

Provided are novel compounds of formula (i): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver x receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver x receptor. Also provided are the compounds of formula (i) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, alzheimer's disease, dermatitis, dyslipidemia, cancer ...
Methods of using btk inhibitors to treat dermatoses
Acerta Pharma B.v.
August 10, 2017 - N°20170224688

In certain embodiments, the invention includes therapeutic methods of using a btk inhibitor to treat dermatoses, such as psoriasis, atopic dermatitis, contact dermatitis, scleroderma, and cutaneous lupus erythematosus. In other embodiments, the methods of the invention further comprise the step of administering a therapeutically effective dose of an anti-inflammatory agent.
Treatment of atopic dermatitis and asthma using rna complexes that target il4ra, trpa1, or ...
Olix Pharmaceuticals, Inc.
August 03, 2017 - N°20170218376

In certain aspects, provided herein are rna complexes (e. G., asymmetric rna complexes, such as asirnas or cell penetrating asirnas) that inhibit il4rα, trpa1, and/or f2rl1 expression and are therefore useful for treating atopic dermatitis or asthma.
Dermatitis Patent Pack
Download + patent application PDFs
Dermatitis Patent Applications
Download + Dermatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dermatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Betalain compositions and methods therefor
Vdf Futureceuticals, Inc.
August 03, 2017 - N°20170216331

Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood.
Method for making herbal soap for alleviating atopic skin disease
Vdf Futureceuticals, Inc.
July 27, 2017 - N°20170209362

Provided is a method for making an herbal soap for alleviating atopic skin disease, the method comprising combining five main medicinal herbs consisting of kalopanacis cortex, amaranthus mangostanus, gardenia jasminoides, lonicerae flos and rumex japonicus houtt with four supplementary medicinal herbs consisting of glycyrrhiza uralensis fischer, mori cortex, phaseoli radiati semen and red ginseng, which serve to increase the efficacies ...
Composition comprising gpcr19 agonist as an active ingredient for preventing or treating allergic dermatitis
Shaperon Inc.
July 13, 2017 - N°20170196895

The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a g protein-coupled receptor19 (gpcr19) agonist, specifically sodium taurodeoxycholate(hy2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and ...
Ibs related testing and treatment
Shaperon Inc.
July 13, 2017 - N°20170196498

Methods and items useful at least therein are provided for ibs related testing and treatment. Disclosed is a patch useful in determining if one or more test materials can cause allergic contact dermatitis in a patient. A kit containing information on use and that may include such a patch and/or test material(s) is also disclosed. A method of ...
Methods of treating atopic dermatitis with il-31 monoclonal antibodies
Zymogenetics, Inc.
June 29, 2017 - N°20170182160

Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for il-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human il-31. Cdr regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein vh and vl domains are attached. The sfv molecules can include ...
Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing ...
Druggability Technologies Ip Holdco Limited
June 15, 2017 - N°20170165237

The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in birt-hogg-dubé syndrome, chronic erosive ...
Binding inhibitor between tctp dimer type ige-dependent histamine releasing factor and receptor thereof, and use ...
Ewha University - Industry Collaboration Foundation
June 08, 2017 - N°20170158761

The present invention relates to a receptor-binding domain of an ige-dependent histamine releasing factor (hrf), and a use thereof, and more specifically, ascertains, as an hrf structual region, and a fl domain and an h2 domain which bind to a receptor of hrf existing in a cell membrane, ascertains the c-terminus domain of the hrf, and ascertains that a material ...
Dermatitis Patent Pack
Download + patent application PDFs
Dermatitis Patent Applications
Download + Dermatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dermatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinase(syk) inhibitors
Guangzhou Shenglu Biotech Limited Company
May 25, 2017 - N°20170145019

The present invention relates to compounds of formula (ia), (ib) or (ic): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, copd, allergic rhinitis, chronic sinusitis, atopic dermatitis, ...
Methods of treating skin disorders using an anti-il-31ra antibody
Zymogenetics, Inc.
May 18, 2017 - N°20170137525

The present invention relates to methods of treating patients suffering from contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination by administering an il-31ra antagonist.
Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort
Zymogenetics, Inc.
May 18, 2017 - N°20170136045

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, dipa-1-5, dipa-1-6, dipa-1-7, dipa-1-8, and dipa-1-9, collectively referred to herein as “dipa compounds”, that are useful, for example, in the treatment of disorders (e. G., diseases) including: sensory ...
Acetylcholinesterase inhibitors for treatment of dermatological conditions
Attillaps Holdings
May 18, 2017 - N°20170135978

Embodiments of the invention involve treating skin afflictions by the topical or oral use of acetylcholinesterase inhibitor. By effectively reducing or eliminating the population of demodex mites in affected skin areas and areas where demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method. Embodiments ...
Method of reducing pruritus using il-31 monoclonal antibodies
Zymogenetics, Inc.
May 11, 2017 - N°20170129952

The present invention relates to methods of treating pruritic diseases, including but not limited to contact dermatitis, atopic dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia wereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination thereof by administering il-31 monoclonal antibodies. The invention provides the hybridomas that ...
Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells
Academia Sinica
May 04, 2017 - N°20170121425

A novel humanized anti-ige antibody is disclosed. The antibody is capable of binding to free ige, membrane-bound ige on b lymphocytes, ige bound by cd23, but not to ige bound by high-affinity ige. Fc receptor on mast cells. The present invention relates to the treatment of ige-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) ...
Enzyme treatment of foodstuffs for celiac sprue
The Board Of Trustees Of The Leland Stanford Junior University
May 04, 2017 - N°20170119860

Administering an effective dose of glutenase to a celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
Methods and compositions for dermatological use comprising clobetasol and halobetasol and biopolymers
Apex Laboratories Private Limited
May 04, 2017 - N°20170119792

Disclosed are compositions comprising topical corticosteroids, such as clobetasol propionate and halobetasol propionate, and a biopolymer in a cream base, wherein the cream base comprises a primary and a secondary emulsifier, a waxy material, a co-solvent, a preservative, an acid, a chelating agent, a buffering agent, and water. The biopolymer comprises chitosan. The compositions disclosed herein are suitable for the ...
Loading